All News
ACP Guidelines on Fracture Prevention in at-risk Adults
The American College of Physicians (ACP) has updated its 2017 recommendations on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults. The full document and guideline can be found in the Annals of Internal Medicine.
Read Article
Cannabis Use for Pain is Common
In states with legalized medical cannabis use, 3 in 10 persons are using cannabis to manage their pain.
Read Article
Abbvie has forcasted sales sales revenues in 2025 for Skyrizi and Rinvoq to be more than $17.5 billion. This year Humira goes off patent. https://t.co/YrIdkEhL7M https://t.co/MuuVYkyXRv
Links:
Dr. John Cush RheumNow ( View Tweet)
Status of #RA; an Egyptian College of Rheumatology study of 10,364 pts from 26 centers.
Mean age 45 yrs, Dz duration 6.4 yrs, onset age 38. (F:M 5.4:1)
DAS28 was 4.4 & HAQ 0.95
RF+ 74%, CCP+ 67%
Rx use: MTX 78%, HCQ 74%, steroids 71%, Biologics 11.6% https://t.co/19omwKqAQl https://t.co/m04QabOwgZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update https://t.co/2lwWc8PqIw https://t.co/uYdYwJofwJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Network meta-analysis of 152 RCTs (17431 pts) comparing efficacy of exercise therapy, NSAIDs, Tylenol for knee or hip osteoarthritis: Found all 3 equivalent at 4 wk, 8 wk and 24 wks. https://t.co/rKck2AacL4 https://t.co/YEAMh9UxTs
Links:
Dr. John Cush RheumNow ( View Tweet)
Remibrutinib in Sjogren's Syndrome
Dr. Michael Putman reports on abstract 1113 presented at ACR22. Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
https://t.co/4UAxMq2z0X https://t.co/kzinfgDGZr
Links:
Dr. John Cush RheumNow ( View Tweet)
PHYSICIANS: Current, routine, outpatient clinic visits - do you require masks
Dr. John Cush RheumNow ( View Tweet)
FDA Accepts Biologics License Application for CT-P13 SC, a Subcutaneous Formulation of Infliximab (Celltrion) that is approved in other countries. https://t.co/G1OIoqk9ga https://t.co/NEWFNlKhlU
Links:
Dr. John Cush RheumNow ( View Tweet)
Neutrophil-to-lymphocyte ratio (NLR) was studied in 205 Idiopathic pulmonary fibrosis (IPF) pts - NLR correlated with lung function, & outcomes - NLR >= 2.9 was associated with a significant 2 fold increased risk of mortality https://t.co/FCuKx2NfeC https://t.co/iIb9uIGBAE
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatology Giants in who passed away in 2022:
Eric Gall
William Wilke
John Winfield
Peter Simkin
Roy Altman
Samuel Strober
James Fries
Robert Lightfoot
Bart Lindsley https://t.co/BX3fGBVre7 https://t.co/ToxZOZHOhU
Links:
Dr. John Cush RheumNow ( View Tweet)
For 2023 - what you going to focus on with your patients? Same ole, same ole means youre not getting better. How about focusing on 2 main messages, mine would be patient "STRENGTH" and "COMPLIANCE" (meaning more Rx education) https://t.co/fEIVYk6Z9m
Dr. John Cush RheumNow ( View Tweet)
"Taking an idea isn’t theft. Taking an idea is an oxymoron. Ideas belong to all of us"
- Seth Godin @ThisIsSethsBlog https://t.co/eY8Tj0c1rF
Dr. John Cush RheumNow ( View Tweet)
2022 Rheumatology Year in Review
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
https://t.co/L7bUUdHqQF https://t.co/aVSXyzF3yy
Links:
Dr. John Cush RheumNow ( View Tweet)
According to a 2022 Review of Physician and Advanced Practitioner Recruiting Incentives" by Merritt Hawkins, orthopedics has the highest salary & pediatrics the lowest. Rheumatology: Low: $200,000, Average: $258,000, High: $325,000 https://t.co/PmmAj9s2Vq https://t.co/nEzp4pWiG0
Links:
Dr. John Cush RheumNow ( View Tweet)
Reuters reports that in 2021, the median annual price was $180,000 for the 1st 30 drugs FDA approved. In 2022, the median annual cost was $222,003 for newly approved drugs. https://t.co/laxw6DacHr https://t.co/kRM7EbrD72
Links:
Dr. John Cush RheumNow ( View Tweet)
Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cmax 33% & AUC 17% if given simultaneously. PPI also lowers AUC by ~33% https://t.co/qXspeRj0eV https://t.co/g7L2OIgFKc https://t.co/egZFKLbNC7 https://t.co/6M3KIG1kTz
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine significantly lowers Alzheimer’s and dementia risk. Study of g 109,124 #RA pts starting HCQ or MTX. showed an 8-16% lower risk. https://t.co/gV4AYHRwmU https://t.co/crbTu1zr3E
Dr. John Cush RheumNow ( View Tweet)
Differential Dx of hyperferritinemia (≥500 μg/) in critically ill ICU pts includes: sepsis, liver disease/failure, hematological malignancy, HLH. Single center study of 2583 patients https://t.co/F5Dz2qpmAy https://t.co/ZWnxHGoQR1
Links:
Dr. John Cush RheumNow ( View Tweet)
ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis
The guideline is based on a systemic review and network meta-analysis conducted by the ACP Center for Evidence Reviews at the Portland Veteran Affairs Research Foundation.
https://t.co/Tx6PnpCEOp https://t.co/AVsnC1yubI
Links:
Dr. John Cush RheumNow ( View Tweet)